Compare VNET Group Inc (VNET) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? VNET Group Inc trades at $7.47 (market cap $2.14B), while State Street SPDR S&P Biotech ETF trades at $159.76. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| VNET | XBI | |
|---|---|---|
Market Cap | $2.14B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $14.03 | $164.28 |
52-Week Low | $6.29 | $86.92 |
Enterprise Value | $5.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.565, up 1.14% today, with a neutral technical signal. The stock shows mixed fundamentals: revenue grew to $9.95B in 2025, but net losses deepened to -$256.77M. Recent news highlights strategic investor entry and AI-driven data center demand, yet earnings misses and a class action settlement pose concerns. Cash flow remains positive from financing, but profitability metrics like ROE at -43.21% signal challenges.
Outlook is cautious; analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio of 50.18% heighten risk. Investors should weigh growth potential from AI expansion against execution and competitive pressures in China's data center market.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
